FORM 10Q
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

    For the quarterly period ended September 30, 1997
                                   ------------------ 


                         Commission file number 0-16005

                           Unigene Laboratories, Inc.
             -----------------------------------------------------
             (Exact name of registrant as specified in its charter)

           Delaware                                         22-2328609
-------------------------------                         -------------------
(State or other jurisdiction of                         (I.R.S. Employer
 incorporation or organization)                         Identification No.)

110 Little Falls Road, Fairfield, New Jersey                  07004
--------------------------------------------                ---------
(Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code: (973) 882-0860
                                                     -------------

--------------------------------------------------------------------------------
(Former  name,  former  address and former  fiscal year,  if changed  since last
report.)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days.     Yes [ X ]  No [  ]

                      APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest  practicable date: Common Stock, $.01 Par Value--
38,411,722 shares as of November 1, 1997
<PAGE>   

                                      INDEX

                           UNIGENE LABORATORIES, INC.

PART I. FINANCIAL INFORMATION                 

Item 1. Financial Statements (Unaudited)

        Condensed balance sheets- 
          September 30, 1997 and December 31, 1996

        Condensed  statements of operations-  
          Three months and nine months ended
          September 30, 1997 and 1996

        Condensed statements of cash flows-
          Nine months ended September 30, 1997 and 1996      

        Notes to condensed financial statements-
          September 30, 1997                                     

Item 2. Management's Discussion and Analysis of Financial   
          Condition and Results of Operations

PART II. OTHER INFORMATION

Item 2.  Changes in Securities                      

Item 6.  Exhibits and Reports on Form 8-K           

SIGNATURES                                          



<PAGE>
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
<TABLE>
<CAPTION>
                           UNIGENE LABORATORIES, INC.
                            CONDENSED BALANCE SHEETS

                                                  September 30      December 31
                                                      1997             1996
                                                 ------------      ------------
                                                  (Unaudited)
<S>                                              <C>               <C>
ASSETS
Current assets:
   Cash and cash equivalents ...............     $  4,199,138      $  4,491,386
   Accounts receivable .....................              380           100,954
   Prepaid expenses and other
      current assets .......................          577,597           882,135
                                                 ------------      ------------
        Total current assets ...............        4,777,115         5,474,475

Property, plant and equipment-net
   of accumulated depreciation and
   amortization ............................        9,594,111        10,356,070
Patents and other assets ...................        1,372,144         1,338,691
                                                 ------------      ------------
                                                 $ 15,743,370      $ 17,169,236
                                                 ============      ============
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
   Accounts payable ........................     $    518,840      $  1,025,136
   Accrued expenses ........................          889,249           685,568
   Notes payable - stockholders ............          610,000           810,000
                                                 ------------      ------------
         Total current liabilities .........        2,018,089         2,520,704

   Note payable - stockholders .............          655,000           655,000
   9.5% convertible debentures .............          502,694         1,283,400
   10% convertible debentures ..............          450,000           850,000
Stockholders' equity:
   Common stock-par value $.01 per share;
      authorized 60,000,000 shares, issued
      and outstanding 38,401,722 shares in
      1997 and 35,352,824 shares in 1996 ...          384,017           353,528
   Additional paid-in capital ..............       63,263,493        55,829,641
   Accumulated deficit .....................      (51,528,892)      (44,322,006)
   Less: Treasury stock, at cost,
      7,290 shares .........................           (1,031)           (1,031)
                                                 ------------      ------------
        Total stockholders' equity .........       12,117,587        11,860,132
                                                 ------------      ------------
                                                 $ 15,743,370      $ 17,169,236
                                                 ============      ============

</TABLE>

See notes to condensed financial statements.
<PAGE>
<TABLE>
<CAPTION>
                                 CONDENSED STATEMENTS OF OPERATIONS
                                            (Unaudited)


                                       Three Months Ended                 Nine Months Ended
                                          September 30                        September 30
                                ------------------------------      ------------------------------
                                     1997              1996              1997             1996
                                ------------      ------------      ------------      ------------
<S>                             <C>               <C>               <C>               <C>
Licensing and
  other revenue ...........     $  3,000,346      $      1,719      $  3,001,830      $    307,528
                                ------------      ------------      ------------      ------------

Operating expenses:
  Research and
    development ...........        2,585,444         2,285,977         6,988,975         5,836,932

  Settlement of contractual
    right (Note D) ........             --                --           1,669,063              --

  General and
    administrative ........          519,940           531,172         1,514,537         1,440,382
                                ------------      ------------      ------------      ------------

                                   3,105,384         2,817,149        10,172,575         7,277,314
                                ------------      ------------      ------------      ------------

Operating loss ............         (105,038)       (2,815,430)       (7,170,745)       (6,969,786)
                                ------------      ------------      ------------      ------------


Other income (expense):
  Interest/other income ...           67,394            24,461           154,801           161,253

  Interest expense ........          (59,643)         (166,129)         (190,943)         (626,771)
                                ------------      ------------      ------------      ------------

                                       7,751          (141,668)          (36,142)         (465,518)
                                ------------      ------------      ------------      ------------

Net loss ..................      $ ( 97,287)      $ (2,957,098)     $ (7,206,887)     $ (7,435,304)
                                ===========       ============      ============      ============

Net loss per share ........     $       --        $       (.11)     $       (.19)     $       (.29)
                                ============      ============      ============      ============

Weighted average number
  of shares outstanding ...       37,934,674        28,127,903        37,041,158        25,732,668
                                ============      ============      ============      ============


</TABLE>
See notes to condensed financial statements.
<PAGE>
<TABLE>
<CAPTION>
                                     UNIGENE LABORATORIES, INC.
                                 CONDENSED STATEMENTS OF CASH FLOWS
                                            (Unaudited)


                                                                         Nine Months Ended
                                                                            September 30,
                                                                  --------------------------------
                                                                      1997                 1996
                                                                  -----------          -----------
<S>                                                               <C>                  <C>
Net cash used for operating activities ..................         $(4,246,738)         $(8,435,855)
                                                                  -----------          -----------
 Investing activities:

   Construction of leasehold improvements ...............             (18,298)              (2,950)
   Purchase of equipment and furniture ..................            (343,143)            (228,954)
   Increase in patents and other assets .................             (92,224)            (110,506)
                                                                  -----------          -----------
                                                                     (453,665)            (342,410)
                                                                  -----------          -----------

Financing activities:

   Sales of stock, net of related expenses ..............           2,936,895              300,440
   Issuance of debt, net of related expenses ............                --              8,137,000
   Exercise of stock options and warrants ...............           1,471,260              631,735
   Repayment of debt ....................................                --                (60,000)
                                                                  -----------          -----------
                                                                    4,408,155            9,009,175
                                                                  -----------          -----------
Net increase (decrease) in cash and
   cash equivalents .....................................            (292,248)             230,910
Cash and cash equivalents at
   beginning of year ....................................           4,491,386              258,627
                                                                  -----------          -----------
Cash and cash equivalents at
   end of period ........................................         $ 4,199,138          $   489,537
                                                                  ===========          ===========

Supplemental cash flow information:

Exchange of notes .......................................                --            $ 3,300,000

Conversion of convertible debentures
   and accrued interest, net of related
   offering expenses into common stock ..................         $ 1,181,136          $ 8,036,265

Conversion of notes payable-stockholders
   into common stock ....................................         $   200,000                 --

Interest paid ...........................................         $    48,415          $   182,923
</TABLE>

See notes to condensed financial statements.
<PAGE>
                           UNIGENE LABORATORIES, INC.
                     NOTES TO CONDENSED FINANCIAL STATEMENTS
                               SEPTEMBER 30, 1997

NOTE A-BASIS OF PRESENTATION

The accompanying  unaudited condensed financial statements have been prepared in
accordance with generally accepted  accounting  principles for interim financial
information and with the  instructions to Form 10-Q and Article 10 of Regulation
S-X.  Accordingly,  they do not include  all of the  information  and  footnotes
required by generally  accepted  accounting  principles  for complete  financial
statements.  In the opinion of management,  all adjustments considered necessary
for a fair presentation have been included. Operating results for the nine month
period ended  September 30, 1997 are not  necessarily  indicative of the results
that  may be  expected  for the  year  ended  December  31,  1997.  For  further
information,  please refer to the Company's  financial  statements and footnotes
thereto  included in the Company's annual report on Form 10-K for the year ended
December 31, 1996.

NOTE B-LICENSING AGREEMENT WITH WARNER-LAMBERT COMPANY

In July 1997,  the  Company  signed a  worldwide  licensing  agreement  for oral
calcitonin with the Parke-Davis division of Warner-Lambert Company.  Pursuant to
the terms of the licensing  agreement,  Unigene  received $6 million in up-front
payments from  Warner-Lambert.  This total consisted of a $3 million purchase of
the Company's  common stock (at a price of  approximately  $4.32 per share which
was the average  closing  price of stock for the 60 day period  ending on August
14, 1997) and a licensing fee of $3 million. Unigene is also eligible to receive
up to an additional  $48.5 million in milestone  payments during the development
program if specified  milestones  are achieved.  If the product is  successfully
commercialized,  the Company will receive  revenue from the sale of raw material
to  Warner-Lambert  and royalties on product  sales.  As part of the  agreement,
Warner-Lambert  will  develop  and  market an oral  calcitonin  product  and the
Company will be the exclusive  supplier of the bulk  calcitonin and will provide
certain analytical support services.

NOTE C - CONVERSION OF NOTES PAYABLE TO STOCKHOLDERS INTO COMMON STOCK

In 1995,  executive  officers of the company,  Warren Levy,  Ronald Levy and Jay
Levy,  and another  member of the Levy family loaned to the Company an aggregate
of $1,905,000.  A total of $440,000 of these loans was repaid in 1996. On May 2,
1997, an aggregate of $200,000 in principal  amount of these loans was converted
into 57,200  shares of the common stock of the Company at a conversion  price of
$3.4965 per share.  The  closing  price of the common  stock on May 1, 1997,  as
reported in the Wall Street Journal, was $3.21875 per share.

NOTE D - SETTLEMENT OF CONTRACTUAL RIGHT

On February 7, 1997, the Company issued an aggregate of 490,000 shares of common
stock to the holders of the Company's 9.5% Senior Secured Convertible Debentures
(the "Debentures") in exchange for the surrender of certain  contractual rights.
The shares were issued in consideration for the cancellation of an obligation of
the  Company  to pay to the  holders a fee equal to 2% of the sum of the  market
value as of December 31, 1998 of the  Company's  common stock plus the principal
amount of all outstanding debt of the Company, less its cash on deposit, up to a
maximum fee of $3,000,000.  The expense  associated  with this  transaction  was
valued at  $1,669,063,  based on a closing price of the common stock of $3.40625
on February 7, 1997.
<PAGE>
NOTE E - CONVERTIBLE DEBENTURES

During the period  January 1, 1997  through  September  30,  1997,  $780,706  of
principal amount of the Company's 9.5% Senior Secured Convertible Debentures was
converted into 697,058 shares of common stock.

During the period  January 1, 1997  through  September  30,  1997,  $400,000  of
principal  amount of the Company's 10% Convertible  Debentures,  plus $40,931 of
accrued interest, was converted into 220,465 shares of common stock.

Item 2.  Management's Discussion And Analysis Of Financial Condition And Results
         Of Operations

Revenues for the three months and nine months ended  September 30, 1997 included
a  license  fee  of  $3,000,000  from  Warner-Lambert  Company  for a  worldwide
licensing  agreement for oral calcitonin.  Revenues for the first nine months of
1996  included a license fee of $300,000  from the  Company's  joint  venture in
China.  Revenues  from  hormone and enzyme  sales were $2,000 and $8,000 for the
nine months ended September 30, 1997 and 1996, respectively.

Research and  development,  the Company's  largest  expense,  increased 13% from
$2,286,000 to  $2,585,000,  and 20% from  $5,837,000 to $6,989,000 for the three
months and nine months ended  September 30, 1997,  respectively,  as compared to
the same  periods in 1996.  The three month  increase was  primarily  related to
regulatory filing fees in Europe and increased salaries. The nine month increase
was  primarily  related  to  regulatory   filing  fees  in  Europe,   regulatory
documentation  preparation  fees and  increased  expenditures  for  supplies and
salaries.

Expenses for the nine month  period  included the  settlement  of a  contractual
right of a third party  against the  Company.  On February 7, 1997,  the Company
issued an aggregate of 490,000  shares of its common stock to the holders of the
Company's 9.5% Senior  Secured  Convertible  Debentures  (the  "Debentures")  in
exchange  for the  cancellation  of an  obligation  of the Company to pay to the
holders a fee equal to 2% of the sum of the market value as of December 31, 1998
of the  Company's  outstanding  common  stock  and the  principal  amount of all
outstanding debt of the Company,  less its cash on deposit,  up to a maximum fee
of  $3,000,000.  The  expense  associated  with this  transaction  was valued at
$1,669,063, based on a closing price of the common stock of $3.40625 on February
7, 1997.

General and  administrative  expenses decreased 2% from $531,000 to $520,000 and
increased 5% from $1,440,000 to $1,515,000, for the three months and nine months
ended September 30, 1997, respectively, as compared to the same periods in 1996.
The three month decrease was primarily due to reduced public relations  expenses
partially  offset by increased  health  insurance costs. The nine month increase
was primarily due to higher insurance and legal expenses.

Interest and other income  increased  $45,000 and decreased $6,000 for the three
months and nine months ended  September 30, 1997,  respectively,  as compared to
the same periods in 1996. The three month  increase was due to additional  funds
available  for  investment in the third quarter as a result of the receipt of $6
million from  Warner-Lambert  in July 1997.  The nine month  decrease was due to
gains on  settlement  of debt  recognized in 1996.  Interest  expense  decreased
$106,000 and $436,000 for the three months and nine months ended  September  30,
1997,  respectively,  as compared to the same periods in 1996 due to conversions
in  1996  and  1997  of a  substantial  portion  of  the  Company's  convertible
debentures.
<PAGE>
As a result  of  increased  revenue  due to the $3  million  licensing  fee from
Warner-Lambert,  as  well as  reduced  interest  expense,  partially  offset  by
increased research and development  expenses,  net loss decreased  $2,860,000 or
97% for the three months ended September 30, 1997 as compared to the same period
in 1996. As a result of increased revenue from the aforementioned  licensing fee
and decreased  interest expense,  mostly offset by increased  operating expenses
which  included the  $1,669,000  settlement  in the first  quarter of 1997,  the
Company's net loss decreased  $228,000 or 3% for the nine months ended September
30, 1997, as compared to the same period in 1996.

As of December  31, 1996,  the Company had  available  for income tax  reporting
purposes  net  operating  loss   carryforwards  in  the  approximate  amount  of
$44,300,000,  expiring  from 1997 through  2011,  which are  available to reduce
future earnings that otherwise would be subject to federal income taxes. For the
nine months ending September 30, 1997, the Company accumulated additional losses
of approximately  $7,200,000. In addition, at December 31, 1996, the Company has
investment  tax credits and research and  development  credits in the amounts of
$64,000 and $1,662,000,  respectively,  which are available to reduce the amount
of future federal income taxes. These credits expire from 1997 through 2011.

The Company follows  Statement of Financial  Accounting  Standards No. 109 (FASB
109),  "Accounting  for  Income  Taxes".  Given the  Company's  past  history of
incurring  operating losses, any deferred tax assets that are recognizable under
FASB 109 have been fully  reserved.  As of January 1, 1997,  under FASB 109, the
Company  had  deferred  tax assets of  approximately  $19,200,000,  subject to a
valuation  allowance of  $19,200,000.  The  deferred  tax assets were  generated
primarily as a result of the Company's  net  operating  losses and available tax
credits.  For the  nine-month  period ended  September  30, 1997,  the Company's
deferred tax assets and valuation  allowances  each  increased by  approximately
$3,100,000.

Statement of Financial Accounting Standards No. 128 "Earnings Per Share" changes
the  reporting  requirements  for earnings  per share (EPS) for publicly  traded
companies by replacing  primary EPS with basic EPS and changing the  disclosures
associated  with this change.  The Company is required to adopt this standard in
the  fourth  quarter  of 1997 and is  currently  evaluating  the  impact of this
standard.

Liquidity and Capital Resources

During  1994,  the Company  completed  construction  of its  peptide  production
facility in  Boonton,  New  Jersey.  The  facility  was  constructed  in a shell
building that is being leased under a ten year net lease which began in February
1994.  The  Company  has two  ten-year  renewal  options as well as an option to
purchase the facility.  The cost of leasehold improvements and process equipment
for this facility, including current validation costs, totaled approximately $12
million.  The improvements  and equipment have been primarily  financed from the
remainder of the $17 million of proceeds received as a result of the exercise by
the warrant  holders of the Company's  Class A Warrants in 1991 and the proceeds
of $2.2 million from the sale of stock in 1994.  There are currently no material
commitments for capital expenditures  relating to either the Boonton facility or
the Company's facility in Fairfield, New Jersey.

The Company, at September 30, 1997, had cash and cash equivalents of $4,200,000,
a decrease of $292,000 from December 31, 1996.
<PAGE>
The Company's  ability to generate cash from  operations  will depend  primarily
upon signing research or licensing  agreements,  achieving defined benchmarks in
such agreements,  receiving  regulatory approval for its licensed products,  and
the commercial sale of these products. As of September 30, 1997, the Company had
one joint venture agreement and one licensing agreement in effect.

In  1996,   the  Company   entered  into  a  joint  venture   agreement  with  a
pharmaceutical company in China. This joint venture contributed $300,000 to 1996
revenues.  It is uncertain whether any additional revenues will be recognized or
received in connection with this joint venture.

In July 1997,  the Company  entered into an agreement  under which it granted to
the Parke-Davis  division of Warner-Lambert  Company, a worldwide license to the
Company's  oral  calcitonin  technology.  Simultaneously  with entering into the
agreement,  the Company  received $6 million in  payments  from  Warner-Lambert,
consisting of a $3 million  licensing fee and a $3 million equity  investment by
Warner-Lambert.  In  addition,  the  Company  is  eligible  to  receive up to an
additional  $48.5  million  in  milestone  payments  during  the  course  of the
development program if specified milestones are achieved, of which $15.5 million
would be received prior to the  commencement of Phase I clinical  studies in the
U.S.  If the product is  successfully  commercialized,  the  Company  also would
receive revenue from the sale of raw material to Warner-Lambert and royalties on
product sales by  Warner-Lambert  and  affiliates.  The Company has retained the
right  to  license  the  use  of  its  technologies  for  injectable  and  nasal
formulations of calcitonin on a worldwide basis.

The Company's cash  requirements  have increased to approximately $9 million per
year with the opening of its peptide manufacturing  facility.  In addition,  the
Company  faces  principal and interest  obligations  over the next several years
under its outstanding  convertible  debentures and other indebtedness.  However,
because of the current  below-market  conversion prices of each of the issues of
debentures, a substantial portion of such debentures has been, and a substantial
portion of the remainder is expected to be,  converted into common stock thereby
decreasing the amount of cash required for principal and interest payments.

After the receipt of $6 million from  Warner-Lambert,  management  believes that
the  Company  currently  has  sufficient  financial  resources  to  sustain  its
operations at the current  level through the first quarter of 1998.  The Company
will require  additional funds to ensure continued  operations beyond that time.
Management  currently believes that the various milestones in the Warner-Lambert
agreement can be achieved on a timely basis thereby  precluding the need for any
outside  financing of the  Company's  operations  in the near term.  Early-stage
milestones primarily relate to the product's performance characteristics,  while
the  latter-stage  milestones  are primarily  related to regulatory  filings and
approvals.

In addition to the  Warner-Lambert  agreement,  management  is actively  seeking
other  licensing  and/or supply  agreements  with  pharmaceutical  companies for
injectable  and nasal forms of calcitonin.  However,  there is no assurance that
any additional  revenue-generating  agreements will be signed. In the absence of
or the delay in achieving  the  Warner-Lambert  milestones  or in signing  other
agreements,  obtaining adequate funds from other sources,  which might include a
debt  or  equity  financing,   would  be  necessary  to  sustain  the  Company's
operations.  However,  there is no  assurance  as to the  terms  on  which  such
additional  funds would be  available or that in such  circumstances  sufficient
funds could be obtained.
<PAGE>
While  the  Company  believes  that  the  implementation  of the  Warner-Lambert
licensing transaction will satisfy the Company's liquidity requirements over the
near-term,  satisfying  the  Company's  long-term  liquidity  requirements  will
require  the   successful   commercialization   of  the   product   licensed  to
Warner-Lambert  or  one of its  other  calcitonin  products.  In  addition,  the
commercialization  of a  calcitonin  product  will  require the Company to incur
additional capital expenditures, including expenditures to expand or upgrade the
Company's  manufacturing  operations to satisfy its supply obligations under the
Warner-Lambert  License agreement.  However,  neither the cost or timing of such
capital expenditures are determinable at this time.


                SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain  statements in this Form 10-Q  constitute  "forward-looking  statements"
within the meaning of the Private Securities  Litigation Reform Act of 1995 (the
"Reform Act"). Such forward-looking  statements involve known and unknown risks,
uncertainties  and other factors that may cause the actual results,  performance
or activities of the Company,  or industry results,  to be materially  different
from any future results,  performance or activities expressed or implied by such
forward-looking  statements. Such factors include: general economic and business
conditions, the financial condition of the Company,  competition,  the Company's
dependence on other  companies to  commercialize,  manufacture and sell products
using the Company's technologies,  the uncertainty of results of preclinical and
clinical testing, the risk of product liability and liability for human clinical
trials,  the  Company's  dependence  on patents  and other  proprietary  rights,
dependence on key management  officials,  the  availability and cost of capital,
the  availability of qualified  personnel,  changes in, or the failure to comply
with, governmental regulations and the failure to obtain regulatory approvals of
the Company's products.
<PAGE>
PART II.  OTHER INFORMATION

Item 2.  Changes in Securities

                  (a) and (b) Not applicable

                  (c) Recent Sales of Unregistered Securities

         On August 19, 1997,  the Company sold for cash 695,066 shares of common
stock to  Warner-Lambert  Company at a price of  approximately  $4.32 per share.
These shares were issued pursuant to a stock purchase agreement dated as of July
15, 1997. All of such shares were issued by the Company without  registration in
reliance on an exemption under Section 4(2) of the Securities Act.

         In the third  quarter of 1997,  the Company sold for cash 64,500 shares
of common stock upon the exercise of an equal number of warrants  exercisable to
purchase one share of common stock at an exercise  price of $2.10 per share.  An
additional  5,012 shares were issued upon the "cashless"  exercise of a total of
10,000  warrants.  The warrants were issued by the Company as  compensation  for
placement  agent  services in connection  with the sale of the 10% Debentures in
March  1996.  The sale of such shares was  effected in reliance on an  exemption
from registration pursuant to Section 4(2) of the Securities Act.

         In the third quarter of 1997, the Company sold for cash an aggregate of
204,000  shares  of common  stock to  certain  financial  and  public  relations
consultants  upon the  exercise of an equal  number of warrants  exercisable  to
purchase  one share of common  stock at exercise  prices  ranging  from $1.38 to
$3.00 per share. The aggregate  consideration received was $320,500. The sale of
such shares was effected in reliance on an exemption from registration  pursuant
to Section 4(2) of the Securities Act.


ITEM 6.  Exhibits and Reports on Form 8-K

                  (a)      Exhibits:

                           3.1.2  Amendment to Certificate of Incorporation 
                                  filed August 22, 1997.

                  (b)      Reports on Form 8-K:

                  July 15, 1997 (announcement of a worldwide licensing agreement
                  for  oral  calcitonin   with  the   Parke-Davis   division  of
                  Warner-Lambert  Company, as well as a stock purchase agreement
                  with Warner-Lambert).
<PAGE>




                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                           UNIGENE LABORATORIES, INC.
                                           -----------------------------
                                                   (Registrant)


                                           /s/ Warren P. Levy
November 12, 1997                          -----------------------------
                                           Warren P. Levy, President
                                           (Chief Executive Officer)


                                           /s/ Jay Levy
November 12, 1997                          -----------------------------
                                           Jay Levy, Treasurer
                                          (Chief Financial Officer and
                                          Chief Accounting Officer)